Nasacort AQ Articles
Teva's ProAir approved for four-year olds
29 September 2008
Symbicort sees similar safety to budesonide
1 September 2008
Merck & Co re-evaluating DME study design
18 August 2008
FDA clears Allergan's Trivaris
23 June 2008
AZ submits sNDA for Symbicot in pediatric asthma
9 June 2008
FDA says CFC inhalers will cease end 2008
9 June 2008
EPO revokes a Symbicort patent
12 May 2008
AstraZeneca submits Symbicort sNDA to US FDA
5 May 2008
Nycomed licenses US rights to ciclesonide drugs to Sepracor in deal worth up to $430M
4 February 2008
Teva enters drug alliance with UCB in USA
21 January 2008
Kos' 3rd-qtr 2006 income rises 17%
27 November 2006
Barr challenges Nasacort patent
15 May 2006
FDA approves GSK's Flovent in children aged four to 11
27 March 2006
FDA OKs Sepracor's Xophenex metered-dose inhaler
21 March 2005
Aventis sells Azmacort to Kos for $200m
15 March 2004
Aventis to boost Allegra production
16 March 2001
Muro gains US backing for Tri-Nasal
4 May 2000
Rhone-Poulenc sales flat for third quarter
8 November 1999
R-P's net income plunges 82%
28 July 1999
Selecting Diseases Suitable For OTC Treatment
4 December 1998
US 2nd-Qtr Rx DTC Spending Rises 25%
6 November 1998
US Rx DTC Ad Spend Set To Beat $1 Billion Again
28 July 1998
Rhone-Poulenc Rorer Slipping In Asthma Market
1 April 1998
High Hopes For New Products At Rhone-Poulenc
5 February 1998
Rhone-Poulenc 3rd Qtr Net Income Up 38.8%
31 October 1997
R-PR Launches Nasacort In The UK
17 March 1997
Strong Year-End Results From R-P Rorer
3 February 1997
R-PR's Nasacort "Better Than" S-P's Claritin
18 November 1996
R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr
4 November 1996
R-PR Submits Two Supplementary NDAs
28 October 1996
Astra USA Wins Sex Allegations Appeal
16 September 1996
R-PR Posts Profits Climb But Flat Turnover In First Half
5 August 1996
GW's Flovent Approved In USA
8 April 1996
R-PR Gets US Approval For Nasacort AQ
16 October 1995
Fisons Bows To Rhone-Poulenc Rorer L1.8B Offer
16 October 1995
R-PR And Fisons Sign Agreement
19 September 1994
BOEHRINGER INGELHEIM RECEIVES NOT APPROVABLE LETTER
14 March 1994
GLAXO'S SEREVENT GAINS US APPROVAL
14 February 1994
BOEHRINGER INGELHEIM GETS GO-AHEAD FOR US TRIALS
19 July 1993
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
Showing 1-45 of 45 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
